Royal Bank of Canada Cuts Perspective Therapeutics (NYSE:CATX) Price Target to $15.00

Perspective Therapeutics (NYSE:CATX) had its target price trimmed by Royal Bank of Canada from $16.00 to $15.00 in a report released on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock.

Other equities research analysts have also issued research reports about the company. Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a research note on Wednesday, March 19th. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Finally, Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Perspective Therapeutics currently has an average rating of “Buy” and an average price target of $14.44.

Perspective Therapeutics Stock Performance

Shares of CATX opened at $2.20 on Thursday. Perspective Therapeutics has a 52 week low of $2.19 and a 52 week high of $19.05. The business has a 50-day simple moving average of $2.94 and a two-hundred day simple moving average of $6.36.

Institutional Investors Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Y Intercept Hong Kong Ltd purchased a new stake in Perspective Therapeutics in the fourth quarter worth about $33,000. Aigen Investment Management LP purchased a new stake in Perspective Therapeutics in the fourth quarter valued at about $34,000. National Bank of Canada FI boosted its stake in Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock worth $35,000 after purchasing an additional 10,998 shares in the last quarter. ProShare Advisors LLC lifted its stake in shares of Perspective Therapeutics by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock worth $49,000 after buying an additional 5,011 shares during the period. Finally, Vontobel Holding Ltd. purchased a new stake in Perspective Therapeutics during the 4th quarter valued at about $51,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.